Navigation Links
Delcath Reconfirms Presentation During American Society of Clinical Oncology 2010 Annual Meeting in Chicago
Date:5/19/2010

NEW YORK, May 19 /PRNewswire-FirstCall/ -- Delcath Systems, Inc. (Nasdaq: DCTH), a development stage, specialty pharmaceutical and medical device company focused on oncology, reconfirmed today that the American Society of Clinical Oncology (ASCO) has accepted an oral presentation of Delcath's Phase III Trial Data comparing percutaneous hepatic perfusion with melphalan (PHP-mel) to the best alternative care for patients with hepatic metastases from ocular or cutaneous melanoma for ASCO's 2010 Annual Meeting, to be held June 4-8, 2010 at McCormick Place in Chicago.

James F. Pingpank, MD, FACS, Associate Professor of Surgery at the University of Pittsburgh School of Medicine and a lead Principal Investigator of the Phase III trial, will present the abstract on June 5 at 3:30 PM, during the Melanoma/Skin Cancer – Oral Abstract Session.  

The abstract concerning Delcath's Phase III Clinical Trial is a late–breaking abstract. Per ASCO policy, all late-breaking abstracts will be publicly released on site at the Annual Meeting. According to ASCO, this process ensures that pivotal research accepted into ASCO's Annual Meeting is presented and discussed in a peer-review setting. These abstracts will also be made publicly available online for the first time over the duration of the Annual Meeting, June 4-8, 2010.

About Delcath Systems, Inc.

Delcath Systems, Inc. is a development stage, specialty pharmaceutical and medical
'/>"/>

SOURCE Delcath Systems, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Delcath Expands Phase III Trial for Metastatic Melanoma to Include University of Maryland Medical Center
2. Delcath Updates Phase III Patient Enrollment as Pivotal Trial Accelerates, Durable Tumor Responses In Phase II Study Also Cited
3. Delcath Expands Phase III Trial for Metastatic Melanoma to Include St. Lukes Cancer Center
4. Delcath Adds Dr. Pamela R. Contag to Its Board of Directors
5. Delcath Continues Expansion of Clinical Trial Centers Offering PHP(TM)
6. Enrollment in Delcaths Pivotal Phase III Metastatic Melanoma Clinical Trial Achieves Seventy-Five Percent Accrual
7. Data Safety Monitoring Board Unanimously Recommends Continuation of Delcaths Phase III Clinical Trial
8. Delcath Systems, Inc. Appoints Dr. Krishna Kandarpa its Executive Vice President R&D and Chief Medical Officer
9. Delcath Systems, Inc. Completes Phase III Study Enrollment
10. Delcath Systems Begins Data Analysis of Phase III Trial
11. Delcath Systems, Inc. to Present at the 12th Annual Needham Growth Stock Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014  A novel wearable injector slightly larger than an Oreo ... to self-inject prescription drugs in the large doses required to ... autoimmune deficiencies, and genetic disorders.  An emerging ... 2018, according to analysts.   Many of these drugs will require ...
(Date:1/14/2014)... N.J. , Jan. 14, 2014 InformEx, ... and sellers of high-value chemistry, will hold the 30 th ... Miami Beach Convention Center from January 21-24. ... 3,500 attendees from top pharmaceutical, fine chemical and specialty chemical ...
(Date:1/14/2014)... 2014 /PRNewswire-iReach/ -- Acumed,s new SLIC Screw System - ... instrumentation to place and insert the screw accurately - ... (e.g. ligament) repair or reconstruction as it holds the ... (Photo: http://photos.prnewswire.com/prnh/20140114/MN45636 ) The SLIC ...
Breaking Medicine Technology:Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 2Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 3
(Date:7/9/2014)... of stromal support cells and immune cells and ... in the development of diseases could open new ... was the conclusion of a review article by scientists ... Nature . , Prof. Peter Carmeliet: "Consider the ... of cancer cells has been examined in minute detail ...
(Date:7/9/2014)... BostonPractices used in policing injection drug users in ... mortality. , A study, conducted by researchers ... Health, in collaboration with St. Petersburg Pavlov State ... had on the health outcomes of a cohort ... use. , Those who were arrested by police ...
(Date:7/9/2014)... French . By ... including brain structure and function, personality, life experiences and genetics, ... to develop binge drinking within the next two years. Impulsivity, ... as life events and a family history of drug use ... not the child had had a single drink at age ...
(Date:7/9/2014)... extinctions around the world have been linked to ... research from the National Institute for Mathematical and ... may also contribute. , In a series ... causes severe hemorrhage of internal organs in frogs, ... frogs if they are exposed to the virus ...
(Date:7/9/2014)... and Infectious Diseases (NIAID), part of the National ... trial of CRS3123, an investigational oral antibiotic intended ... difficile ) infection. CRS3123 (previously known as REP3123) ... growth while sparing normal intestinal bacteria. , The ... healthy men and women ages 18 to 45 ...
Breaking Medicine News(10 mins):Health News:Wake-up call for more research into cell metabolism 2Health News:BU researchers relate arrests with HIV risk environment 2Health News:What drives a child to abuse alcohol? 2Health News:Study predicts ranavirus as potential new culprit in amphibian extinctions 2Health News:NIH launches Phase I clinical trial of novel drug to treat Clostridium difficile infection 2
... Food Safety in Sunshine State by Using ... Food-Borne Illness, LANSING, Ill., Feb. 7 National ... Egg restaurants in,Lakewood Ranch and Sarasota, Fla., will now ... for all dishes requiring eggs., By using Davidson,s ...
... Lotus Pharmaceuticals,Inc. (OTC Bulletin Board: LTUS) ("Lotus" ... People,s Republic of China ("PRC"), today,announced that ... owned,subsidiary of Lotus, has implemented cost saving ... costs by approximately 50%., The environmentally-friendly ...
... hours and more than 300 people in the UK die ... with permanent disabilities. Now researchers will work on a potential ... the medical charity Meningitis UK. , Although vaccines exist to ... vaccine to protect against all strains, including the most common ...
... E. Borlaug Hall of Laureates, DES MOINES, Iowa, ... a $1 million contingent donation to fund the establishment,of ... Des Moines. The donation,will support the transformation of the ... Hall of Laureates and will be administered,through DuPont business ...
... New Fresh Plum Juice Boasts Digestive Health Benefits with 60 Percent Less ... ... Due to the overwhelming,success of PlumSmart plum juice, Sunsweet Growers Inc. has ... three grams of fiber in each glass and only 11 grams of,sugar, ...
... All Existing Markets -, LONG BEACH, N.Y., Feb. ... PMQCW), the third largest long-term care,pharmacy, today announced that ... across all four of its institutional pharmacies,which serve a ... City,metropolitan area, as well as parts of New Jersey, ...
Cached Medicine News:Health News:Popular Florida Restaurant Leads Hospitality Industry by Converting to Pasteurized Shell Eggs Usage 2Health News:Lotus Pharmaceuticals, Inc. Implements Environmentally-friendly Cost Saving Strategies 2Health News:Meningitis vaccine study gets £200,000 boost 2Health News:DuPont Pledges $1 Million to World Food Prize 2Health News:DuPont Pledges $1 Million to World Food Prize 3Health News:Sunsweet Introduces PlumSmart Light(R) 2Health News:Chem Rx Surpasses 65,000 Residents Served 2
Subretinal Fluid Cannula, Curved; 20g (0.90) x 1-1/2" (38mm); 12mm Flexible Tubing Extends 6mm Beyond Tip; Curved at 65°....
Injection Cannula, Straight; 20g (0.90) x 1" (25mm); Tip Extension: 5mm, 30g (0.30)....
...
PremierEdge™ Slit Knives....
Medicine Products: